• The initial phase of the 2024 drilling program, held in July, hit multiple high-grade intercepts over 2,198 meters at the company’s flagship Thundercloud property in Ontario.
• Assay results confirmed the high-grade mineralization discovered in 2022 and 2023 to the east of the Pelham Zone, and the presence of a strong gold system on the property.
• Consistent high-grade mineralization was intercepted, between 5 to 8+ g/t and going as high as 24.53 g/t, at less than 100 meters below the surface.
• The fall drilling campaign is set to commence before the end of September.

Dynasty (TSX.V: DYG) (OTC: DGDCF), a Canadian mineral exploration company currently focused on gold exploration in North America with projects located in the Manitou-Stormy Lake greenstone belt in Ontario and the Midas gold camp in Nevada, released assay results for the initial phase of the 2024 drill program at its flagship Thundercloud property. Held in July, phase one of the 2024 drill program comprised 2,198 meters for Thundercloud, which is located in one of the most prolific mining areas in North America – in the Archean Manitou-Stormy Lakes Greenstone belt, 47 kilometers southeast of Dryden in northwestern Ontario.

According to a company press release, the goal of the July drilling campaign was to test extensions for eastern and western limits of the already defined mineralization (https://ibn.fm/tIJDH). The drilling campaign successfully intersected high-grade gold mineralization of 5.13 g/t over 18 meters (from 97.5m to 115.5m), including 9.3 g/t over 4.5 meters and numerous 5 to 8+ g/t over 1.5m in hole number TC24-02. Most holes were shallow within 200 meters of surface.

Assay results for an additional 30 meters are still pending, but results so far confirm the existence of high-grade mineralization discovered in 2022 and 2023 extending to the east of the Pelham Zone, with consistent high grade mineralization between 5 to 8+ g/t and going as high as 24.53 g/t, at less than 100 meters below the surface. The results confirm the existence of a strong gold system on the property, favorable for more gold discovery during upcoming drill programs.

The drilling program also intersected broad zones of lower grade gold mineralization, with grades up for 1.73 g/t from 25 meters below surface with intercepts between 50 and 136 meters in length.

Highlights of the July 2024 Drilling Campaign

• Hole TC24-02:

10.62g/t over 1.5m between 100.5m and 102m

24.53 g/t over 1.5m between 112.5m and 114m

• Hole TC24-04:

13.29 g/t over 1.5m between 169.5m and 171m

8.73 g/t over 1.5m between 172.5m and 174m

• Hole TC24-11:

6.23 g/t over 1.5m between 196.5m and 198m

5.54 g/t over 1.5m between 202.5m and 204m

• Hole TC24-13:

5.6 g/t over 1.5 m between 93m and 94.5m

6.69 g/t over 1.5m between 94.5m and 96m

• Hole TC24-14:

1.25 g/t over 9m between 49.5m and 58.5m

“Since our first drill program on Thundercloud in 2022, July of 2024 drilling continued to intersect broad zones of near-surface mineralization with extensive high-grade intervals in most holes. This demonstrates the richness of the gold system on the property for potentially high-grade and bulk-tonnage mineralization,” said Ivy Chong, President and CEO of Dynasty Gold.

The July campaign results further establish the continuity of mineralization at Pelham over a strike length of 450 meters and at 150 to 200 meter depth. Overall, three holes were drilled 300 meters west of Pelham, in an area with historic exploration pits and historic drilling that reported intercepts of up to 30.6 grams over 0.77 meters. However, no significant mineralization was intersected in these holes, which is likely because of their location within footwall of the north dipping mineralization.

With more than sufficient funding for its 20024 and 2025 exploration programs, Dynasty Gold is now set to commence fall drilling at the Thundercloud property, before the end of September, to test the remaining 90% of the property untested by drilling. This area has huge potential for more gold discovery. “During the fall exploration program, we will continue to drill to expand Pelham Resource along strike and at depth, simultaneously expand our footprint to the remaining untested 90% of the property,” Chong said.

For more information about the company, visit www.DynastyGoldCorp.com, and see its Investor Presentation at https://ibn.fm/WR6yZ.

NOTE TO INVESTORS: The latest news and updates relating to DGDCF are available in the company’s newsroom at https://ibn.fm/DGDCF

• California’s recent minimum wage hike to $20 per hour has already driven many restaurants out of business
• Nightfood Holdings is capitalizing on this shift by diversifying with the acquisition of Future Hospitality Ventures
• Future Hospitality Ventures is an early entrant in the burgeoning Robotics-as-a Service market as billions of dollars shift from labor to automation in the coming years

The recent and unprecedented increase in California’s minimum wage for foodservice workers has forced every restaurant and hospitality business statewide to evaluate their future existence and viability.

Acquisition and development company Nightfood Holdings (OTCQB: NGTF), a pioneer in the sleep-friendly nighttime snack market, identified the opportunity created by the radically shifting landscape, and invested aggressively into automation technologies. This move positions Nightfood at the intersection of service and cutting-edge technology, reflecting an immediate industry shift towards automation as a necessity for survival.

In April, the new minimum wage law went into effect, mandating paying at least $20 per hour to employees of limited-service restaurant chains with at least 60 locations nationwide. The wage hike is a very real problem for companies already on the edge. Consider Rubio’s Coastal Grill, which closed 48 underperforming restaurants in California in response.

In addition high-flying industry darling Shake Shack (NYSE: SHAK) made the shocking decision to immediately shutter six restaurants in California because the mandatory jump in hourly pay made it impossible for those locations to provide acceptable returns to shareholders.

The Rise of Robotics

In the relentless battle for survival, there’s currently an “adapt or die” environment. Companies like McDonald’s and Shake Shack are adapting by seeking solutions such as self-service order kiosks, robotic servers and food prep automation.

This shift isn’t just a long-term maximization strategy; it is an immediate survival necessity. These operations need to move away from expensive and unpredictable human labor.

Nightfood understands this harsh reality and took decisive action in acquiring Future Hospitality Ventures. This bold move reflects the company’s commitment to aggressively identify and exploit explosive market trends in the hospitality, food services and consumer goods sectors.

Future Hospitality Ventures saw the writing on the wall, launching its automation and robotics solutions in California before the minimum wage increase. The acquisition gave Nightfood an early start on this massive opportunity. “Incorporating Future Hospitality’s advanced AI-enabled robotic solutions positions us at the forefront of innovation in the hospitality sector at this critical point in time,” said Sonny Wang, newly appointed chief executive officer of Nightfood, when discussing the acquisition.

According to Hoovers, a story in the Wall Street Journal reported that some fast-food restaurants were laying off people before the new law even went into effect on April 1, 2024. They also can and do slash benefits to control margins. Other ways restaurants have tried to offset the rising cost are to eliminate overtime and tap the brakes on any new restaurant development.

This is a simple matter of the laws of survival. Restaurants, which are constantly bombarded with criticisms about smaller portions and higher prices, must manage despite radical landscape changes that are out of their control.

And there’s a trickle-down effect. For instance, an Associated Press story alerted readers to California schools having labor crisis when it comes to cafeteria workers since the minimum wage increase went into effect.

Automation isn’t something that’s just nice to have, and this is not expected to be a slow and gradual evolution; restaurants simply have no choice but to embrace automation as a lifeline to avoid going out of business.

Innovating for the Future

Nightfood’s strategic expansion into automation is a response to the challenge faced by the hospitality and foodservice industry, factors which drive operational costs out of the black and into the red. The company’s focus on acquiring Future Hospitality Ventures and wholesale packaging supplier CarryOutSupplies underscores its commitment to capitalizing on powerful industry trends.

The significant benefits offered by robotics are both company-facing and consumer-facing. By automating tasks like food preparation and order processing, businesses can improve efficiency, reduce errors, and maintain service quality while navigating the financial and labor pressures.

The evolution of automation technologies enables businesses to survive this current labor crisis long enough so that they may thrive in the future and capitalize on long-term growth opportunities. Make no mistake, this has all the makings of an extinction event.

Nightfood’s focus on robotic automation puts the company at the heart transfer of billions of dollars of expenditures from labor to automation.

Navigating Challenges and Opportunities

The recent changes in California’s labor laws highlight the complex interplay through operational viability. While the subject of opportunity cost weighs heavily on these industries, the embrace of automation is simply no longer optional.

Nightfood is offering solutions for companies that must adapt or face obsolescence. By investing in robotic automation and packaging solutions, NGTF is aggressively taking advantage of an opportunity to shape the future of the food service and hospitality sectors.

For more information, visit the company’s website at https://nightfood.com/.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• SOBRsafe, developer of advanced alcohol detection and monitoring technology, has, after its recent expansion into the behavioral health market, already secured 35 new customer accounts year-to-date
• The company recently unveiled a national campaign targeting more than 45,000 behavioral health decision makers across the country
• The campaign is now expected to significantly build the SOBRsafe brand, grow demand and increase the company’s market share

SOBRsafe (NASDAQ: SOBR), the developer of advanced transdermal alcohol detection and monitoring technology, has made substantial progress in 2024. The company has secured 35 new customer accounts this year, a substantial increase over 2023. The success followed the company’s late 2023 decision to focus on the behavioral health market.

“We first entered our core market of behavioral health in Q4 2023, where our technology is re-inventing the continuum of care by reducing redundancy, eliminating paper trails, creating digital records, improving billing processes, and most importantly, creating more time and focus for clinical practice,” said SOBRsafe CEO and Chairman Dave Gandini in an Aug. 12 press release (https://ibn.fm/80CpT).

Gandini observes that the validation in this new market not only aligns with the company’s sales strategy but is also “the first and most important step in building our industry brand.” He further noted that it empowers the “range of continued customer adoption – from single location providers with fewer than 25 patients, to providers with multiple facilities and larger patient populations.”

Encouraged by the understanding that the market validation enjoyed so far empowers even more customer adoption, the company recently launched a national campaign targeting behavioral health providers. SOBRsafe is undertaking the campaign in partnership with prominent national agencies drawn from the public relations and digital and social media marketing spaces. The campaign seeks to introduce the SOBRsafe(TM) technology to a large and growing market, and is designed to capture over 4 million projected views over the next year and present the technology to more than 45,000 behavioral health decision makers (https://ibn.fm/b2dYO).

“Consistent with our strategy, we established our technology in the behavioral health vertical with our first revenue-generating customers in 2024. We are working with national communications leaders to build the SOBRsafe brand, grow demand and gain market share. This effort will move us closer to improving patient outcomes and saving lives,” said Gandini of the campaign.

The SOBRsafe(TM) technology is a scalable, patent-pending software platform, which integrates with the company’s non-invasive devices, the SOBRcheck(TM) and SOBRsure(TM), to produce statistical, measurable user and business data.

SOBRcheck is a stationary passive alcohol screening and identity verification device. It features two sensors, one which compares biometric data points from the finger to confirm the user’s identity and another that detects or senses alcohol excreted through the pores of the fingertip. The device provides accurate and instantaneous results and can be connected to the cloud for data aggregation. Additionally, it is hygienic, as it does not require users to provide samples of their blood, urine or saliva.

On the other hand, SOBRsure(TM) is a fitness-style wearable wristband designed for continuous, real-time transdermal alcohol monitoring. It remotely sends geolocation data and removal alerts. And in an industry where stigma can and does affect patients’ ability to look for or continue with treatment and recover, the SOBRsure product is silent and discreet, meaning it easily passes off as any other fitness wristband.

By integrating with these devices, the SOBRsafe software collects and transmits data, presenting it as insights to parents, clinicians, administrators, and more. The company is nonetheless exploring possible integrations with third-party systems and licensing by non-competing companies. SOBRsafe is banking on the fact that its eponymous technology can be deployed across multiple other devices for various uses (https://ibn.fm/ssn88).

For more information, visit the company’s website at www.SOBRsafe.com.

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR

• The event was attended by Annovis Founder, President and CEO Maria L. Maccecchini, Ph.D.
• Dr. Maccecchini discussed the company’s notable achievements and plans for the future and held a Q&A session with attendees.
• The company CEO also participated in an expert panel discussing innovative non-amyloid approaches in Alzheimer’s disease.
• Recent clinical trials of the company’s lead compound buntanetap obtained encouraging results and was shown to improve cognition in both Alzheimer’s and Parkinson’s patients.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), participated in the H.C. Wainwright 26th Annual Global Investment Conference, held virtually, as well as in-person at the Lotte New York Palace Hotel in New York City, Sept. 9-11, 2024 (https://ibn.fm/BEBy5).

The company was represented at the event by Founder, President and CEO Maria L. Maccecchini, Ph.D., who gave a detailed presentation highlighting Annovis’s recent achievements, followed by a Q&A session on Sept. 10. Dr. Maccecchini also participated in a panel discussion focusing on innovative non-amyloid approaches in Alzheimer’s disease, featuring representatives from Annovis, Anavex Life Sciences Corp. (NASDAQ: AVXL) and Longeveron Inc. (NASDAQ: LGVN).

Dr. Maccecchini’s presentation included an overview of the company’s recent advancements and strategic direction, coming after several productive months for Annovis, with encouraging data on lead compound buntanetap’s performance in three pivotal studies. Buntanetap works by targeting multiple pathways involved in neurodegenerative diseases. It inhibits the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression.

The three recent studies that yielded encouraging results include:

• Phase 2/3 Alzheimer’s Disease Clinical Trial: Data from this study showed that buntanetap significantly improved cognition in patients with early AD, with a 3.3-point improvement on the ADAS-Cog11 test after three months of treatment, compared to a 0.3-point improvement in the placebo group. A later analysis on June 11 demonstrated that buntanetap was effective in improving cognition among high-risk APOE4 carriers, showing a 3.15-point improvement. It also showed that buntanetap was as safe in APOE4 carriers as non-carriers, an impressive advantage over existing disease-modifying therapies.
• Phase 3 Parkinson’s Disease Clinical Trial: Study data indicated that buntanetap led to significant improvements in both the Unified Parkinson’s Disease Rating Scale (“MDS-UPDRS”) and cognition across several PD subpopulations. Buntanetap showed a strong response in individuals diagnosed with PD for more than three years as well as in those with postural instability and gait disorder. The lead compound was also found to halt cognitive decline in all enrolled patients and improved cognition in those with mild dementia.
• Combination Trial with GLP-1 Agonist Dulaglutide: Preclinical data demonstrated that buntanetap synergistically enhances cognition beyond normal levels, when used in combination with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (“Trulicity”(R)) in a mouse model of AD.

Among other notable recent achievements was the introduction of a new crystalline form of buntanetap with improved properties, offering significant advantages over the less structured, old semi-crystalline form, including better solubility and stability as well as an additional 20 years of patent life.

Annovis filed the new crystalline form with the International Patent Cooperation Treaty and a provisional patent for the manufacturing of this crystalline form, covering the entire synthesis process. The company also received approval from the Food and Drug Administration to continue the clinical development with this new form of buntanetap. Additionally, the company was granted a U.S. patent for the use of buntanetap in the treatment of acute traumatic brain injury, expanding its coverage, since acute indication claims had been previously granted in Europe and worldwide.

“These milestones position us strongly as we move closer to providing much-needed treatments to patients,” Dr. Maccecchini said in a recent press release, commenting on the business updates (https://ibn.fm/DOh6H).

For more information about the company, visit www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

The Chief Commercial Officer Summit, organized by Dynamic Global Events (“DGE”), returns to Philadelphia, PA, this fall. The 3rd Chief Commercial Officer Summit is scheduled for October 23-24, 2024, taking on a hybrid format. The in-person event is being held at The Inn at Penn – Hilton Hotel, conveniently located just six miles from the Philadelphia International Airport. Organizers will also be streaming the event live to a virtual audience, with the online option also allowing attendees to follow the sessions whenever and wherever on demand.

The 3rd Chief Commercial Officer Summit is expected to bring together leaders and professionals in the biotech, pharma, and medical device and diagnostics sectors. And, as the annual meeting place for chief commercial officers (“CCOs”), the summit promises to introduce professionals to market leaders making a difference in their respective spaces.

Additionally, the event forms an ideal setting for attendees to learn about the fundamental vision and out-of-box strategies for driving commercial growth and operational excellence. The summit will examine the potential impact of the 2024 presidential election on the life sciences industry; discuss the skills, capabilities and processes for moving from clinical to commercial; the CCO career path; and it will also look into how M&A or shifts in leadership can transform organizational culture.

Attendees will also gain insight into when to independently navigate the market, engage in co-promotion, or fully out-license assets, as well as how to integrate a commercial perspective into clinical trial recruitment to enhance communications. Moreover, they will learn about ways to negotiate market access with channel partners such as payers, wholesalers, distributors, and pharmacy benefit managers (“PBMs”).

With a lineup of distinguished speakers drawn from companies in the biopharma and medical devices spaces, and multiple opportunities to network, the two-day event is the best opportunity to gain insights, establish relationships, and generate fresh ideas. This list of speakers includes the likes of Christina Larkin, CEO of Mobius Care; Geoff Birkett, CCO of Ensysce Biosciences; Charmaine Lykins, a Commercial Strategy Advise and former CCO of MapLight Therapeutics; John Harlow, CCO of Melinta Therapeutics; and Ferrell Simon, CCO of Trevi, just to mention a few.

The summit kicks off early on October 23 with opening remarks from Robert Francomano, CCO of Synox Therapeutics, followed by a presentation titled “Potential Impact of 2024 Presidential Election on the Life Sciences Industry” by Jason Slotnik, Partner at Health Policy Strategies. The next item on the agenda will be a fireside chat, followed by a networking refreshment break, with attendees then returning for additional educational presentations, a second fireside chat, and a panel discussion summarizing CCO best practices. The second day is equally jam-packed, with a cocktail of insightful presentations and networking sessions that are all curated around this year’s theme: Vision and Strategy for Driving Commercial Growth and Excellence.

To learn more, visit https://ibn.fm/V4lww

The Finovate platform showcases innovations, technologies and new applications to an audience consisting of senior executives, experts, financial institutions, credit unions, and VCs, from all across the globe. Every demo hosted by fintech companies demonstrates unique innovations, technology and products.

Finovate events are meticulously curated conferences for and by executives of the fintech spectrum. Thousands of executives, companies and investors from around the globe attend the conferences to learn the latest trends and technology in the fintech world. These visionaries offer sharp insights and strategies on the important aspects of the industry. Upcoming and established companies/individuals are selected by the Finovate team to give demos where they pitch their business/services.

The outstanding demos that catch everyone’s attention are selected for the Finovate Awards. This year, the Finovate team selected 24 winners of the 2024 Finovate Awards. The selection involved a rigorous process, and every entrepreneur, company or organization competed with several other competitors to find a place in the winning slot.

The Finovate Awards congratulate veterans and newcomers who have delivered state-of-the-art products and services to the financial sector. All winners have given phenomenal contributions to the fintech landscape and developed cutting-edge solutions.

To learn more, please visit https://ibn.fm/vlSsH.

• The company is seeking an accelerated approval regulatory pathway for CNM-Au8^® for ALS.
• The FDA agreed to an in-person meeting to reevaluate Clene’s submission.
• Lead drug candidate CNM-Au8 has been shown to restore and protect neurological function, offering hope for patients with neurodegenerative conditions.
• The FDA meeting will be held before the end of November and will be attended by top FDA officials and key opinion leaders in ALS, biostatistics and biomarkers.

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), announced an upcoming meeting with the U.S. Food and Drug Administration (“FDA”) leadership to discuss lead candidate CNM-Au8^®.

According to a company press release, the in-person meeting will be held before the end of November 2024 and will focus on the company’s CNM-Au8 biomarker and related clinical and survival data for ALS. The meeting will be attended by FDA’s Director of the Office on New Drugs, the Director of the Office of Neuroscience, and the Division of Neurology 1 (“DN1”) review team, as well as recognized key opinion leaders in ALS, biostatistics and biomarkers (https://ibn.fm/UgpSj).

The meeting comes after Clene submitted CNM-Au8 biomarker and clinical efficacy data to the FDA in a Type C meeting request, seeking approval to file a New Drug Application (“NDA”) using the accelerated approval regulatory pathway for ALS. DN1 responded that Clene’s briefing package for CNM-Au8 was not supportive of an NDA submission under the accelerated approval pathway. However, following further discussions, the FDA agreed to meet in person to reevaluate Clene’s submission.

“Clene looks forward to the opportunity to have experts present their views to the FDA and address questions on ALS biomarkers, related clinical endpoints and survival data, all of which Clene believes are essential for the understanding of its CNM-Au8,” the company release said.

The company also voiced appreciation for the FDA’s use of process and regulatory flexibility to obtain the best outcome for people living with ALS.

CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide (“NAD”) pathway while reducing oxidative stress.

An oral suspension of gold nanocrystals, CNM-Au8 works by improving cellular energy production and utilization, crucial for maintaining neuronal health. Mitochondrial dysfunction is a common pathway leading to neuronal death in neurodegenerative diseases. By targeting this dysfunction, CNM-Au8 aims to provide neuroprotection and promote remyelination, potentially altering the course of these debilitating conditions, providing a dual benefit that sets it apart from existing therapies.

Clene has conducted extensive clinical trials to evaluate the safety and efficacy of CNM-Au8. Two recent independently conducted Phase 2 clinical trials, RESCUE-ALS and HEALEY ALS Platform Trials, yielded encouraging results, as participants saw improvement in survival rates and delays in clinical worsening, defined as first occurrence of death (or death and permanent assisted ventilation), tracheostomy, need for invasive ventilatory support, or feeding tube placement.

Additionally, Clene has more than 700 patient-years of safety data that show no significant safety concerns or safety trends identified. No serious adverse events have been identified as related to CNM-Au8 treatment by any clinical trial investigators to date. CNM-Au8 has the potential to capture a significant share of the therapeutic market for both ALS and MS by working in conjunction with existing treatments to improve function and increase survival rates. 

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• New battery technologies are being researched and developed to rival lithium-ion batteries in terms of efficiency, cost and sustainability.
• Lithium-sulfur batteries could offer advantages over lithium-ion batteries, including increased range and storage capacity.
• Companies working in this space include Lion Battery Technologies Inc. founded by Platinum Group Metals Ltd. and Anglo American Platinum Limited.

The battery of choice these days, relied on to power everything from digital devices to electric vehicles and even energy-storage systems, is the lithium-ion battery. However, lithium-ion technology has its drawbacks; consequently, other battery solutions are being developed, including lithium sulfur. Through its subsidiary Lion Battery, Platinum Group Metals (NYSE American: PLG) (TSX: PTM) is working to strengthen its foothold in the lithium-sulfur space.

“Most battery-powered devices, from smartphones and tablets to electric vehicles and energy storage systems, rely on lithium-ion battery technology,” reported a recent Built-In article (https://ibn.fm/qVVJL). “Because lithium-ion batteries are able to store a significant amount of energy in such a small package, charge quickly and last long, they became the battery of choice for new devices.

“But new battery technologies are being researched and developed to rival lithium-ion batteries in terms of efficiency, cost and sustainability,” the article continued. “While lithium-ion batteries have come a long way in the past few years, especially when it comes to extending the life of a smartphone on full charge or how far an electric car can travel on a single charge, they’re not without their problems. The biggest concerns — and major motivation for researchers and startups to focus on new battery technologies — are related to safety, specifically fire risk, and the sustainability of the materials used in the production of lithium-ion batteries, namely cobalt, nickel and magnesium.”

The article noted that many of these new battery technologies aren’t reinventing the wheel; rather, they’re exploring the potential of different materials when it comes to powering devices or storing energy. Such is the case with lithium-sulfur technology, which relies on sulfur for the battery’s cathode. Because sulfur is more sustainable than nickel and cobalt, which are often used in a battery anode with lithium metal, the possibilities are promising.

Lion Battery was jointly formed in 2019 by Platinum Group and Anglo American Platinum to accelerate the development of next-generation battery technology using platinum and palladium. Since inception the Lion team has focused on the development of proprietary lithium sulfur technology and enhancing the performance of existing commercial lithium-ion (“NMC”) chemistries. Lion has a sponsored research agreement with Florida International University (“FIU”) including exclusive rights to all intellectual property developed and will lead commercialization efforts. To date the U.S. Patent and Trademark Office has granted five patents related to research conducted by FIU on behalf of Lion.

“Lithium-sulfur batteries are believed to be more efficient than lithium-ion batteries, which could increase the range and storage capacity of electric vehicles,” Built-In reported. “Additionally, sulfur is affordable and abundant, which could mean lower costs. And since the manufacturing process for these batteries is like the one used for lithium-ion batteries, the same facilities could also be used for production. Advancements in lithium-sulfur batteries have also resulted in faster charging and made them useful for raising the storage capacity of renewable energy technologies.”

Lion Battery has engaged The Battery Innovation Center (“BIC”) in Newberry, Indiana, to help drive commercialization of its next generation platinum and palladium based battery chemistries. The BIC is completing independent small scale and large scale trials to validate Lion’s proprietary platinum and palladium based electrode composition, slurry and films in both lithium-sulfur and lithium-ion (“NMC811”) coin and pouch cells. Collaboration also includes additional research and development focused on improving performance and scale-up with the goal of creating prototypes for commercialization consideration in late 2024. Lion’s target is to develop batteries with specific energies that are 20% to 100% higher than current technologies while meeting or exceeding their present cycle lives.

For more information, visit the company’s website at www.PlatinumGroupMetals.net.

NOTE TO INVESTORS: The latest news and updates relating to PLG are available in the company’s newsroom at https://ibn.fm/PLG

The 2024 MoneyShow/TradersEXPO Orlando will be held on Oct. 17-18 at the Omni Orlando Resort at ChampionsGate in Central Florida. The MoneyShow conference is an interactive platform for networking, education and collaborative experiences. Attendees will get valuable insights from money experts on personal portfolio management right before the U.S. presidential elections. Distinguished financial leaders will grace the conference stage to guide traders and investors with their experience and wisdom.

MoneyShow has a 43-year history of offering expertise, connections and education, to active traders and investors, helping them best position their portfolios in all market environments. MoneyShow’s platform connects traders and investors with experts who are skilled portfolio managers, financial journalists, best-selling authors, market analysts, and newsletter editors.

At the Orlando conference, attendees will learn critical insights on the market and economy. They can use these tips and advice to streamline their financial and investment decisions. Attendees can also make long-term business connections and engage directly with eminent speakers in ways they could never otherwise do.

The three-day event will include discussion panels, keynote speaker sessions, and training workshops for executives, traders, and investors, helping them identify the best market opportunities and learn how to execute seamless and timely trade entries and exits.

Meanwhile, the on-site exhibit hall will showcase the latest products, technologies and financial tools that attendees can test-drive on the spot. Attendees will learn to capitalize on the latest market trends during live trading and podcast recording sessions.

Participants will also get to collect autographed copies of their favorite books and get a chance to get their queries answered on-the-spot. Recreational activities are also available, allowing conference-goers to unwind and connect with other attendees while enjoying drinks in a casual setting.

To learn more, please visit https://ibn.fm/pbi4d

• Europe’s energy landscape has undergone significant changes recently, in part due to the geopolitical tensions between Russia and Ukraine.
• Türkiye’s energy demand is growing rapidly with an expanding economy and population.
• Amid this growth, Trillion Energy International has emerged as a significant player in the natural gas sector.

The demand for natural gas in Europe and Türkiye is on the rise, driven by a combination of geopolitical, economic and environmental factors. As the world grapples with energy security and sustainability, natural gas has emerged as a crucial component of the energy mix in these regions. The increased demand for natural gas is prompting a call for enhanced production, with companies such as Trillion Energy International (CSE: TCF) (OTCQB: TRLEF), a Canadian oil and gas exploration and production company, playing a pivotal role in meeting these needs.

Europe’s energy landscape has undergone significant changes in recent years, in part due to the geopolitical tensions between Russia and Ukraine (https://ibn.fm/OcTh0). The conflict has disrupted traditional gas supplies from Russia, prompting European nations to seek alternative sources of energy. Natural gas is seen as a crucial transition fuel that can help bridge the gap between coal and renewable energy sources. It is cleaner than coal and oil and produces fewer carbon emissions, making it an essential part of Europe’s strategy to reduce greenhouse gas emissions while ensuring a stable energy supply.

In Türkiye, the situation is somewhat different but equally compelling. Türkiye’s energy demand is growing rapidly due to its expanding economy and population (https://ibn.fm/6QD1K). The country’s strategic location as an energy transit hub has increased its role in regional energy dynamics. Türkiye is working to diversify its energy sources to reduce dependence on imports and enhance energy security. Natural gas is a key element in this strategy, providing a reliable and relatively cleaner energy source to support economic growth and meet domestic energy needs.

Amid this growing demand, Trillion Energy International has emerged as a significant player in the natural gas sector. The company has been actively involved in natural gas production in Türkiye, where it operates the South Akçakoca Sub-Basin (“SASB”) gas project. This project is strategically important for Türkiye’s energy goals because it aims to increase domestic natural gas production and reduce reliance on imported energy.

A recent update on Trillion Energy International’s production highlights the progress the company is making (https://ibn.fm/kazL9). According to the latest article, Trillion Energy has reported significant advancements in its production capabilities. The company has successfully completed several key milestones in the SASB project, including drilling and testing new wells. These efforts have led to increased production rates and have enhanced the overall efficiency of the gas field.

Specifically, the company noted that the Akcakoca-3 well at the SASB Gas Field was perforated in July 2024 and has now been put into production, producing at 4.66 million cubic feet per day.

“We are thrilled with the strong performance of Akcakoca-3 and the successful flow tests at Alapli-2,” said Trillion Energy CEO Arthur Halleran. “All the wells except Bayhanli-2 have now been put on production or flow tested to ascertain if gas is present and capable of production in the 4-½-inch production tubing. This confirms that once the 2-3/8-inch is installed in the wells, the gas will flow in a predictable and stable manner.”

The report emphasizes Trillion Energy’s commitment to further expanding its operations. The company is focused on increasing its production capacity to meet the region’s rising demand for natural gas. By investing in new technology and exploring additional reserves, Trillion Energy is well positioned to contribute significantly to the natural gas supply in Europe and Türkiye.

Trillion Energy International is focused on oil and natural gas production for Europe and Türkiye with natural gas assets in Türkiye. The company is 49% owner of the SASB natural gas field, a Black Sea natural gas development, and has a 19.6% interest (except three wells with 9.8%) in the Cendere oil field.

For more information regarding Trillion Energy, visit the company’s website at www.TrillionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to TRLEF are available in the company’s newsroom at https://ibn.fm/TRLEF